Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging in Resectable Stage IIIA NSCLC
NCT02607423Phase 2Withdrawn
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Nov 2015
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Rate of mediastinal downstaging at 9 weeks. Planned start Nov 2015; status: withdrawn.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02607423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607423.